1. Home
  2. KALV vs UVSP Comparison

KALV vs UVSP Comparison

Compare KALV & UVSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALV
  • UVSP
  • Stock Information
  • Founded
  • KALV N/A
  • UVSP 1876
  • Country
  • KALV United States
  • UVSP United States
  • Employees
  • KALV N/A
  • UVSP N/A
  • Industry
  • KALV Biotechnology: Pharmaceutical Preparations
  • UVSP Major Banks
  • Sector
  • KALV Health Care
  • UVSP Finance
  • Exchange
  • KALV Nasdaq
  • UVSP Nasdaq
  • Market Cap
  • KALV 796.4M
  • UVSP 910.5M
  • IPO Year
  • KALV N/A
  • UVSP 1989
  • Fundamental
  • Price
  • KALV $10.95
  • UVSP $30.51
  • Analyst Decision
  • KALV Strong Buy
  • UVSP Hold
  • Analyst Count
  • KALV 8
  • UVSP 2
  • Target Price
  • KALV $26.43
  • UVSP $29.00
  • AVG Volume (30 Days)
  • KALV 1.5M
  • UVSP 91.7K
  • Earning Date
  • KALV 09-11-2025
  • UVSP 10-22-2025
  • Dividend Yield
  • KALV N/A
  • UVSP 2.90%
  • EPS Growth
  • KALV N/A
  • UVSP 12.33
  • EPS
  • KALV N/A
  • UVSP 2.73
  • Revenue
  • KALV $1,426,000.00
  • UVSP $298,354,000.00
  • Revenue This Year
  • KALV N/A
  • UVSP $12.42
  • Revenue Next Year
  • KALV $213.43
  • UVSP $4.67
  • P/E Ratio
  • KALV N/A
  • UVSP $11.13
  • Revenue Growth
  • KALV N/A
  • UVSP 4.09
  • 52 Week Low
  • KALV $7.30
  • UVSP $22.83
  • 52 Week High
  • KALV $17.28
  • UVSP $32.86
  • Technical
  • Relative Strength Index (RSI)
  • KALV 27.85
  • UVSP 49.89
  • Support Level
  • KALV $11.93
  • UVSP $29.20
  • Resistance Level
  • KALV $12.43
  • UVSP $31.23
  • Average True Range (ATR)
  • KALV 0.60
  • UVSP 0.74
  • MACD
  • KALV -0.22
  • UVSP -0.10
  • Stochastic Oscillator
  • KALV 6.17
  • UVSP 53.91

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About UVSP Univest Financial Corporation

Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.

Share on Social Networks: